AbbVie (NYSE: ABBV) has shown strong performance over the past decade, despite a recent slowdown due to the expiration of Humira’s patent. With this challenge behind them, AbbVie’s future looks promising, particularly supported by its key immunology products, Skyrizi and Rinvoq, which have exceeded expectations. These medications are approved for various conditions, contributing significantly to the company’s growth. Investing in AbbVie could be beneficial over the next five years.
